Foghorn Therapeutics Inc.
| NASDAQ: FHTX | Healthcare / Biotechnology / USA |
| 4.03 | -0.1900 | -4.50% | Vol 107.50K | 1Y Perf -51.88% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 3.69 | ASK | 4.30 | ||
| Open | 4.21 | Previous Close | 4.22 | ||
| Pre-Market | - | After-Market | 4.03 | ||
| - - | - -% |
| Target Price | 21.25 | Analyst Rating | Strong Buy 1.29 | |
| Potential % | 427.30 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 37.91 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -1.37 | Earnings Rating | — | |
| Market Cap | 168.70M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.28 | |
| Beta | 2.39 |
Today's Price Range 4.014.26 | 52W Range 4.119.97 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -30.87% | ||
| 1 Month | -49.05% | ||
| 3 Months | -41.17% | ||
| 6 Months | -30.40% | ||
| 1 Year | -51.88% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -207.28 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -35.21 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -96.11 | |||
Return on invested Capital Q | -31.41 | |||
Return on invested Capital Y | -53.19 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.40 | ||||
| 11.12 | ||||
| 17.42 | ||||
| 1.10 | ||||
| 1.20 | ||||
| 5.77 | ||||
| 11.12 | ||||
| 0.58 | ||||
| -49 870 500.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.80 | ||||
| 6.80 | ||||
| 0.66 | ||||
| 2.19 | ||||
| -255.20 | ||||
| Leverage Ratio | 9.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -689.90 | ||||
| -669.10 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.04M | ||||
| 0.36 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.73 | -0.70 | 4.11 |
| Q01 2023 | -0.68 | -0.73 | -7.35 |
| Q04 2022 | -0.59 | -0.69 | -16.95 |
| Q03 2022 | -0.60 | -0.62 | -3.33 |
| Q02 2022 | -0.53 | -0.66 | -24.53 |
| Q01 2022 | -0.40 | -0.65 | -62.50 |
| Q04 2021 | -0.74 | -0.77 | -4.05 |
| Q03 2021 | -0.66 | -0.71 | -7.58 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -0.72 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 107.50K |
| Shares Outstanding | 41.86K |
| Shares Float | 25.08M |
| Trades Count | 1.21K |
| Dollar Volume | 447.11K |
| Avg. Volume | 108.34K |
| Avg. Weekly Volume | 170.33K |
| Avg. Monthly Volume | 86.37K |
| Avg. Quarterly Volume | 68.32K |
Foghorn Therapeutics Inc. (NASDAQ: FHTX) stock closed at 4.03 per share at the end of the most recent trading day (a -4.5% change compared to the prior day closing price) with a volume of 107.50K shares and market capitalization of 168.70M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 85 people. Foghorn Therapeutics Inc. CEO is Adrian Gottschalk.
The one-year performance of Foghorn Therapeutics Inc. stock is -51.88%, while year-to-date (YTD) performance is -36.83%. FHTX stock has a five-year performance of %. Its 52-week range is between 4.11 and 9.97, which gives FHTX stock a 52-week price range ratio of -1.37%
Foghorn Therapeutics Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 11.12, a price-to-sale (PS) ratio of 17.42, a price to cashflow ratio of 1.10, a PEG ratio of -, a ROA of -35.21%, a ROC of -96.11% and a ROE of -207.28%. The company’s profit margin is -%, its EBITDA margin is -669.10%, and its revenue ttm is $15.04 Million , which makes it $0.36 revenue per share.
Of the last four earnings reports from Foghorn Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Foghorn Therapeutics Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Foghorn Therapeutics Inc. is Strong Buy (1.29), with a target price of $21.25, which is +427.30% compared to the current price. The earnings rating for Foghorn Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Foghorn Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Foghorn Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.77, ATR14 : 0.47, CCI20 : -178.75, Chaikin Money Flow : -0.35, MACD : -0.85, Money Flow Index : 26.80, ROC : -33.61, RSI : 20.69, STOCH (14,3) : 0.70, STOCH RSI : 0.00, UO : 25.81, Williams %R : -99.30), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Foghorn Therapeutics Inc. in the last 12-months were:
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
CEO: Adrian Gottschalk
Telephone: +1 617 586-3100
Address: 100 Binney Street, Cambridge 02142, MA, US
Number of employees: 85
